During the past decade, there has been an increase in the use of continuous glucose monitoring (CGM) technology in clinical practice1 and in clinical trials and research2 for diabetes. Three main factors have led to this increase. First, advances in CGM technology have improved the accuracy of glucose readings, improved the comfort and practicality of small sensors, and reduced or eliminated the need for calibration with blood-glucose readings. Second, the standardisation of CGM readouts between different manufacturers has enabled clinicians and users to quickly understand the essential metrics of glycaemic control and to objectively measure improvements after treatments and interventions.